- Home
- KPLT vs ESLA Comparison
KPLT vs ESLA Comparison
Compare KPLT & ESLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KPLT
- ESLA
- Stock Information
- Founded
- KPLT 2012
- ESLA 2021
- Country
- KPLT United States
- ESLA United States
- Employees
- KPLT N/A
- ESLA N/A
- Industry
- KPLT Diversified Commercial Services
- ESLA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- KPLT Consumer Discretionary
- ESLA Health Care
- Exchange
- KPLT Nasdaq
- ESLA Nasdaq
- Market Cap
- KPLT 52.2M
- ESLA 48.9M
- IPO Year
- KPLT N/A
- ESLA N/A
- Fundamental
- Price
- KPLT $5.75
- ESLA $1.52
- Analyst Decision
- KPLT Hold
- ESLA Strong Buy
- Analyst Count
- KPLT 1
- ESLA 1
- Target Price
- KPLT $10.00
- ESLA $16.00
- AVG Volume (30 Days)
- KPLT 128.6K
- ESLA 416.9K
- Earning Date
- KPLT 11-12-2025
- ESLA 11-12-2025
- Dividend Yield
- KPLT N/A
- ESLA N/A
- EPS Growth
- KPLT N/A
- ESLA N/A
- EPS
- KPLT N/A
- ESLA N/A
- Revenue
- KPLT $280,839,000.00
- ESLA N/A
- Revenue This Year
- KPLT $22.88
- ESLA N/A
- Revenue Next Year
- KPLT $10.98
- ESLA N/A
- P/E Ratio
- KPLT N/A
- ESLA N/A
- Revenue Growth
- KPLT 16.15
- ESLA N/A
- 52 Week Low
- KPLT $5.08
- ESLA $0.73
- 52 Week High
- KPLT $24.34
- ESLA $3.15
- Technical
- Relative Strength Index (RSI)
- KPLT 25.89
- ESLA 38.89
- Support Level
- KPLT $5.50
- ESLA $1.67
- Resistance Level
- KPLT $6.43
- ESLA $1.99
- Average True Range (ATR)
- KPLT 0.93
- ESLA 0.37
- MACD
- KPLT -0.12
- ESLA -0.16
- Stochastic Oscillator
- KPLT 8.63
- ESLA 1.21
About KPLT Katapult Holdings Inc.
Katapult Holdings Inc. is a technology-driven lease-to-own platform that integrates with omni-channel retailers and e-commerce platforms to power the purchase of everyday durable goods for underserved U.S. non-prime consumers. It is an e-commerce-focused FinTech company offering a lease-purchase solution to consumers and enabling essential transactions at the merchant point of sale. Katapult is associated with hundreds of retailers across the United States.
About ESLA Estrella Immunopharma Inc.
Estrella Immunopharma Inc is a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors. Estrella's mission is to harness the evolutionary power of the human immune system to transform the lives of patients fighting cancer and autoimmune diseases.